Anaplastic Transformation of Follicular Thyroid Carcinoma in Pulmonary Metastasis With Gradually Progressive Intra-tumoral Cavitation: A Case Report

Hajime Torizuka 1, Minoru Inoue 1, Yusuke Iizuka 2, 1, Yosuke Yamada 3, Takashi Mizowaki 3

1. Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine, Kyoto, JPN
2. Department of Radiation Oncology, Shizuoka City Shizuoka Hospital, Shizuoka, JPN
3. Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, JPN

Corresponding author: Minoru Inoue, miinoue@kuhp.kyoto-u.ac.jp

Abstract
Anaplastic transformation of differentiated thyroid cancer is rare but clinically important because of the dismal prognosis after anaplastic transformation. Therefore, cases and findings of anaplastic transformation must be accumulated, which could ultimately lead to an earlier diagnosis and an improved prognosis. Here, we present a case of anaplastic transformation of follicular thyroid carcinoma (FTC) in a pulmonary metastatic lesion associated with gradually progressive tumor cavitation. The patient with FTC was diagnosed with multiple lung metastases three years after surgery for the primary tumor and metastatic neck lymph nodes. Annual treatment with radioactive iodine resulted in disease stability for 10 years. However, one lung metastasis in the left lower lobe gradually enlarged and was associated with intra-tumoral cavitation. The growing lung nodule was resected and pathologically diagnosed as an anaplastic transformation of FTC. Fourteen months after diagnosis, the patient died of pneumothorax caused by pleural dissemination despite multiple treatment interventions. This case highlights pulmonary metastasis with progressive cavitary lesions as a potential early sign of the anaplastic transformation of differentiated thyroid cancer.

Categories: Otolaryngology, Radiation Oncology, Nuclear Medicine
Keywords: differentiated thyroid carcinoma, anaplastic thyroid cancer, pulmonary metastases, tumor cavitation, i-131 radioiodine treatment

Introduction
The incidence of thyroid cancer has increased worldwide over the past three decades [1]. Most cases are differentiated thyroid carcinomas (papillary or follicular thyroid carcinoma, (PTC or FTC), which are routinely managed surgically with or without radioactive iodine (RAI) therapy. In general, PTC and FTC are biologically indolent with excellent prognoses, with 10-year survival rates exceeding 80% [2]. However, a small subset of PTC and FTC cases transform into anaplastic carcinoma. Anaplastic transformation occurs within primary tumors [3], metastatic lymph nodes [4], and metastatic lesions in distant organs [5]. Patients with anaplastic transformation have a poor prognosis, with six-month survival rates of only 35% [6]. Therefore, it is essential to accumulate further cases of anaplastic transformation in PTC and FTC, which could lead to the identification of predictive imaging features and biomarkers for detecting patients with an elevated risk of anaplastic transformation. Herein, we report a case of anaplastic transformation of FTC arising from a lung metastasis that exhibited gradually progressive intra-tumoral cavitation.

Case Presentation
A 33-year-old woman had been aware of her slowly growing thyroid gland since 1997. In 2002, she recognized a palpable mass in the right thyroid, which led to the detection of biopsy-proven thyroid cancer. Right thyroid lobectomy and cervical lymph node dissection were performed in the same year. Postoperative pathological examination revealed FTC of the primary tumor and metastatic cervical lymph nodes (pT3N1bM0, pStage I (UICC 8th edition)). An additional total thyroidectomy was not performed as per the patient’s request. In 2005, multiple asymptomatic lung metastases were identified on thoracic computed tomography (Figures 1A, 1B). Therefore, the patient underwent residual thyroidectomy and subsequent RAI therapy (iodine-131 (131I): 4.81 GBq) in 2006. An uptake of 131I was observed in the thyroid bed and lung metastases (Figures 1C, 1D).
The patient further underwent nine doses of 131I between 2006 and 2016 (4.81 GBq×3 and 5.55 GBq×6). In each treatment, 131I was well distributed to the lung metastases, and the patient had sustained stable disease (i.e., no remarkable changes in serum thyroglobulin (Tg) concentration or lung metastasis size). However, one metastatic nodule in the left lower lobe displayed a slight increase associated with intra-tumoral cavitation (Figures 2A, 2B, 2E, 2F) and weakened uptake of 131I after the last two RAI therapies. In June 2019, this lung nodule exhibited remarkable growth from 9 mm to 52 mm (Figures 2C, 2D, 2G, 2H), whereas the serum Tg level decreased from 194.6 ng/mL to 98.4 ng/mL.

Fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) revealed significant 18F-FDG uptake only in this nodule (Figures 3A, 3B), indicating dedifferentiation or anaplastic transformation of
the lung metastasis of FTC.

Consequently, in July 2019, a left lower lung lobectomy was performed to establish the diagnosis and determine the optimal treatment strategy.

Histopathological evaluation of the resected lung (Figure 4A) revealed that the enlarged tumor was highly pleomorphic (Figure 4B), paired-box gene 8 (PAX8) positive (Figure 4C), and thyroid transcription factor-1 (TTF-1) negative (Figure 4D), compatible with anaplastic thyroid carcinoma [7].

Other small nodules in the resected lung exhibited follicular differentiation and were PAX8 and TTF-1 positive (data not shown). Thus, anaplastic transformation in the pulmonary metastasis of FTC was diagnosed. Based on this diagnosis, 24 mg/day of lenvatinib was initiated. However, the antitumor effect of lenvatinib was partial (i.e., a mild decrease in serum Tg level). The patient exhibited pleural dissemination in October 2019 (Figure 5A), lymph node metastases in the neck and mediastinum in January 2020, bone metastases in the zygomatic bone in February 2020, and multiple brain metastases in July 2020 (Figure 5B). Although a series of palliative external beam radiotherapy treatments were administered (25 Gy/5 fractions for the pleural dissemination, 17.5 Gy/8 fractions for the lymph nodes in the mediastinum, and 20 Gy/5 fractions of whole brain radiotherapy for multiple brain metastases), sufficient shrinkage of the tumor and palliation of the symptoms were not achieved. Finally, the patient died of respiratory failure due to pleural dissemination-derived pneumothorax in October 2020 (Figure 5C).
Discussion
Anaplastic thyroid carcinoma (ATC) accounts for 2% of all thyroid cancers and has an extremely poor prognosis, with one-year survival rates of approximately 5% [8]. The majority of ATC cases are considered to be transformed from pre-existing PTC or FTC, whereas some arise de novo from pre-existing multinodular goiters. Various genetic and epigenetic alterations related to anaplastic transformation (such as TERT promoter and TP53) have been identified [4]. However, knowledge of the clinical signs of anaplastic transformation remains limited. Rapid proliferation without elevation of the tumor marker Tg [9], loss of uptake of RAI [10], and newly acquired uptake properties of 18F-FDG [10] are potential signs of anaplastic transformation of PTC and FTC. In addition, the current case exhibited gradually progressive intra-tumoral cavitation before the diagnosis of anaplastic transformation of the FTC.

Several reports have described the formation of intra-tumoral cavitation in ATC. Micro-vessel density in the tumor tissue of ATC is significantly lower than that in the tumor tissue of PTC and FTC, which may contribute to the development of intra-tumoral cavitation through tumor necrosis mediated by a lack of blood supply [11]. Furthermore, pharmacological inhibition of tumor angiogenesis by bevacizumab [12] and lenvatinib [13] also promotes pulmonary tumor cavitation. The increasing demand for blood supply within the tumor undergoing anaplastic transformation may lead to intra-tumoral cavitation, further suggesting that the formation of intra-tumoral cavitation may be an early sign of anaplastic transformation of pulmonary metastases.

The establishment of therapeutic strategies against ATC is warranted because standard treatment approaches for differentiated thyroid cancers (i.e., thyroidectomy and RAI therapy) are mostly ineffective for ATC owing to the disease extent and loss of the ability to uptake iodine [14]. The efficacy of systemic therapy (e.g., paclitaxel with or without carboplatin, doxorubicin with or without docetaxel), sorafenib, pazopanib, and lenvatinib), as well as radiotherapy, is also limited [15-19]. In cases of BRAF V600E-mutant ATC, combined therapy with dabrafenib and trametinib has proven more effective, with a median overall survival of 15 months and a 12-month survival rate of 52% [20]. Unfortunately, the Japanese national health insurance system does not cover the costs of dabrafenib plus trametinib treatment for ATC. Therefore, this regimen was not considered in the present case.

Conclusions
The presented case demonstrates the anaplastic transformation of FTC in pulmonary metastasis. Additionally, it highlights the development of intra-tumoral cavitation as a potential early sign of anaplastic transformation in the pulmonary metastasis of differentiated thyroid cancer. Although further investigations and the accumulation of similar cases are needed, our findings may stimulate future research exploring the radiologic features of anaplastic transformation and ultimately support clinicians by facilitating an early diagnosis.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322/caac.21660
2. Perros P, Boelaert K, Colley S, et al.: Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014, 81 Suppl 1:1-122. 10.1111/cen.12515
3. Yamazaki H, Iwasaki H, Suganuma N, et al.: Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530/EDM-19-0085
4. Odate T, Oishi N, Kawai M, et al.: Progression of papillary thyroid carcinoma to anaplastic carcinoma in metastatic lymph nodes: solid/insular growth and hobnail cell change in lymph node are predictors of subsequent anaplastic transformation. Endocr Pathol. 2021, 32:347-56. 10.1007/s12022-021-09674-1
5. Hosoda K, Kusama K, Yanagisawa N, et al.: Anaplastic transformation of thyroid cancer in mesentery metastases presenting as intestinal perforation: a case report. Surg Case Rep. 2020, 6:194. 10.1186/s40792-020-00959-x
6. Maniakas A, Dadu R, Busaidy NL, et al.: Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 2020, 6:1597-404. 10.1001/jamaoncol.2020.3362
7. Lloyd RV, Osamura RY, Kloppel G, Rosai J: Anaplastic thyroid carcinoma. WHO Classification of Tumours of Endocrine Organs. Lloyd RV, Osamura RY, Kloppel G, Rosai J (ed): World Health Organization, Geneva, Switzerland; 2017. 10:104-6.
8. Lowe NM, Loughran S, Slevin NJ, Yap BK: Anaplastic thyroid cancer: the addition of systemic chemotherapy to radiotherapy led to an observed improvement in survival—a single centre experience and review of the literature. ScientificWorldJournal. 2014, 2014:674583. 10.1155/2014/674583
9. Wiseman SM, Griffith OL, Deen S, et al.: Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg. 2007, 142:717-27; discussion 727-9. 10.1001/archsurg.142.8.717
10. Solomon JP, Wen F, Jih LJ: Anaplastic transformation of papillary thyroid cancer in the retroperitoneum. Case Rep Pathol. 2015, 2015:241308. 10.1155/2015/241308
11. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997, 275:547-50. 10.1126/science.275.5299.547
12. Iida T, Yahana T, Nakagaki S, Adachi T, Kondo Y: A rupture of a lung metastatic lesion of colon cancer, leading to pneumothorax caused by bevacizumab. Intern Med. 2016, 55:5125-9. 10.2169/internalmedicine.55.7155
13. Murayama D, Yamamoto Y, Matsui A, Yasukawa M, Okamoto S, Toda S, Iwasaki H: Lung cavitation in patients with anaplastic thyroid cancer treated with lenvatinib. Gland Surg. 2022, 11:963-9. 10.21037/gs-22-71
14. Fagin JA, Wells SA Jr: Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016, 375:1054-67. 10.1056/NEJMra1510193
15. Cabanillas ME, Ryder M, Jimenez C: Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019, 40:1573-604. 10.1210/er.2019-00007
16. Smallridge RC, Copland JA: Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010, 22:486-97. 10.1016/j.cion.2010.03.013
17. Bible KC, Suman VJ, Meneee ME, et al.: A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012, 97:3179-84. 10.1210/jc.2012-1520
18. Savvides P, Nagah G, Laverut P, et al.: Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013, 23:600-4. 10.1089/thy.2012.0103
19. Wirth LJ, Brosse MS, Sherman EJ, et al.: Open-label, single-arm, multicenter, Phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol. 2021, 39:2559-66. 10.1200/JCO.20.03095
20. Subbiah V, Kreitman RJ, Wainberg ZA, et al.: Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022, 33:406-15. 10.1016/j.annonc.2021.12.014